Localised carcinoma of the prostate: A paradigm of uncertainty

Postgraduate Medical Journal

Volumn 73, Issue 865, 1997, Pages 691-696

  Sandhu, Sarbjinder S ^a   Kaisary, Amir V ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Prostate cancer

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AGE; BONE SCINTISCANNING; CANCER INCIDENCE; CANCER STAGING; DIET; FAMILY HISTORY; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PREVALENCE; PROSTATE BIOPSY; PROSTATE CARCINOMA; PROSTATECTOMY; RACE; REVIEW; THORAX RADIOGRAPHY;

EID: 0030659679     PISSN: 00325473     EISSN: None     Source Type: Journal    
DOI: 10.1136/pgmj.73.865.691     Document Type: Review

References (42)

1. Scardino PT, Weaver R, Hudson MA. Early detection of prostate cancer. Hum Pathol 1992; 23: 211-22.
2. Spring WB, Alden MW. Evaluation of needle biopsy in the diagnosis of prostatic carcinoma. Can Med Assoc J 1954; 70: 179-85.
3. Cooner WH, Mosley BR, Rutherford CL Jr, et al. Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. J Ural 1990; 143: 1146-54.
4. Hodge KK, McNeal JE, Stamey TA. Ultra-sound guided transrectal core biopsies of the palpably abnormal prostate. J Urol 1989; 142: 66-70.
5. Hodge KK, McNeal JE, Terris MK, Stamey TA. Random systematic versus directed ultra-sound guided transrectal core biopsies of the prostate. J Urol 1989; 142: 71-5.
6. Blackwell KL, Bostwick DG, Myers RP, Zincke H, Oesterling JE. Combining prostate specific antigen with cancer and gland volume to more reliably predict pathological stage: the influence of PSA-cancer density. J Urol 1994; 151: 1565-70.
7. Oesterling JE, Cooner WH, Jacobsen SJ, Guess HA, Lieber MM. Influence of patient age on the serum PSA concentration. An important clinical observation. Urol Clin N Am 1993; 20: 607-20.
8. Benson MC, Whang IS, Pantuck A, et al. Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. J Urol 1992; 147: 815-21.
9. Seaman EK, Whang IS, Cooner W, et al. Predictive value of prostate specific antigen density for the presence of micrometastic carcinoma of the prostate. Urology 1994; 43: 645-8.
10. Brawer MK, Aramburu EAG, Chen GL, et al. The inability of prostate specific antigen index to enhance the predictive value of prostate specific antigen in the diagnosis of prostate cancer. J Urol 1993; 150: 369-73.
11. Carter HB, Pearson JD, Metter JE, et al. Longitudal evaluation of prostate specific antigen in men with and without prostate disease. JAMA 1992; 267: 2215-20.
12. Partin AW, Carter HB, Chan DW, at al. Prostate specific antigen in the staging of localised prostate cancer: influence of tumour differentiation, rumour volume and benign hyperplasia. J Urol 1990; 143: 747-52.
13. Blackwell KL, Bostwick DG, Myers RP, Zinke H. Combining prostate specific antigen with cancer and gland volume to more reliably predict pathological stage: the influence of PSA-cancer density. J Urol 1994; 151: 1565-70.
14. Catalona WJ, Smith DS, Ratliff TL, et al. Measurement of prostate specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991; 324: 1156-61.
15. Hoisaeter PA, Norlen BJ, Norming U, et al. Imaging in the diagnosis and assessment of prognosis in localised prostate cancer. Consensus conference on diagnosis and prognostic parameters in localised prostate cancer, Stock-holm, Sweden, May 12/13, 1993. Scand J Urol Nephrol 1994; 162(suppl): 89-106.
16. McCarthy P, Pollack HM. Imaging of patients with Stage D prostatic carcinoma. Urol Clin N Am 1991; 18:35-53.
17. Phillips ME, Kressel HY, Spritzer CE, et al. Prostatic disorders: MR imaging at 1.5T. Radiology 1987; 164: 386-92.
18. Platt JF, Bree RL, Schwab RE. Accuracy of CT in the staging of carcinoma of the prostate. AJR 1987; 149: 315-8.
19. Bezzi M, Kressel HY, Allen KS, et al. Prostatic carcinoma: MR imaging at 1.5T. Radiology 1988; 169: 339-46.
20. McClennan BL. Transrectal ultrasound of the prostate. Is the technology leading the science. Radiology: 1988; 168: 571-5.
21. Danhert WF, Hamper UM, Walsh PC, et al. The echogenic focus in prostatic sonograms with xeroradiographic and histopathologic correlation. Radiology 1986; 159: 95-100.
22. Rifkin MD, Danhert W, Kurtz AB. State of the art: endorectal sonography of the prostate gland. AJR 1990; 154: 691-700.
23. Scardino PT, Shinohara K, Wheller TM, et al. Staging of prostate carcinoma: value of ultrasonography. Urol Clin North Am 1989; 16: 713-24.
24. Lentle BC, Mcgown DG, Dierich H. Technetium-99m polyphosphate bone scanning in carcinoma of the prostate. Br J Urol 1974; 128: 543-8.
25. Paulson DF. The impact of current staging procedures in assessing the disease extent of prostatic adenocarcinoma. J Urol 1979; 121: 300-2.
26. Kabalin JN, McNeal JE, Johnstone IM, Stamey TA. Serum prostate specific antigen and the biologic progression of prostate cancer. Urology 1995; 46: 65-70.
27. Naryan P, Fournier G, Gajendran V, et al. Utility of preoperative serum PSA concentration and biopsy Gleason score in predicting risk of pelvic lymph node metastases in prostate cancer. Urology 1994; 44: 519-24.
28. Gibbons RP. Localised prostate carcinoma. Cancer 1993; 72: 2865-72.
29. George NJR. Natural history of localised of prostate cancer managed by conservative therapy alone. Lancet 1988; 1: 494-7.
30. Johansson JE, Adami HO, Andersson SO, Bergstrom R, Kruserno UB, Kraaz W. Natural history of localised of prostate cancer: a population based study in 223 untreated patients. Lancet 1989; 1: 799-803.
31. Whitmore WF Jr, Warner JA, Thompson IM. Expectant management of localised prostatic carcinoma. Cancer 1991; 67: 1091-6.
32. Adolfsson J, Carstensen J, Lowhagen T. Deferred treatment in clinically localised prostatic cancer. Br J Urol 1992; 169: 183-7.
33. Kirk D, for the MRC Prostate Cancer Working Party and Investigators. Hormone therapy in advanced prostate cancer - report of the Medical Research Council 'immediate' versus 'deferred' treatment study. Br J Urol 1996; 77(suppl 1): 204,52.
34. Bagshaw, MA, Kaplan ID, Cox RC. Radiation therapy for localised disease. Cancer 1993; 71: 939-52.
35. Walsh PC. Radical retropubic prostatectomy: an anatomic approach. In: Walsh PC, Retik AB, Stamey TA, Vaughn ED Jr, eds, Campbell's Urology, 6th edn. Philadelphia: WB Saunders, 1992; pp 2865-86.
36. Gibbons RP, Correa RJ Jr, Brannen GE, Weissman RM. Total prostatectomy for localised prostate cancer: long term results. J Urol 1989; 141: 564-6.
37. Paulson DF, Moul JW, Walther PJ. Radical prostatectomy for clinical stage T1-2N0M0 prostatic adenocarcinoma: long term results. J Urol 1990; 144: 1180-4.
38. Epstein JI, Carmichael MJ, Pizov G, Walsh PC. Influence of capsular penetration on progression following radical prostatectomy: a study of 196 cases with long-term follow-up. J Urol 1993; 150: 135-41.
39. Parkes C, Wald NJ, Murphy P, George L, Watt HC, Kirby R. Prospective obsevational study to assess value of prostate specific antigen as screening for prostate cancer. BMJ 1995; 311: 340-3.
40. Andriole GL, Catalona WJ. Using PSA to screen for prostate cancer. Ural Clin N Am 1993; 20: 647-51.
41. Middleton RG, Thompson IM, Austenfeld MS, et al. Prostate cancer clinical guidelines panel summary report on the management of clinically localised prostate cancer. J Urol 1995; 154: 2144-8.
42. Waxman J, Sheer D. Is prostate cancer worth diagnosing? Lancet 1995; 346: 1177-8.